202 related articles for article (PubMed ID: 27910927)
41. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: implications for therapy of cutaneous T-cell lymphoma.
Stephen S; Morrissey KA; Benoit BM; Kim EJ; Vittorio CC; Nasta SD; Showe LC; Wysocka M; Rook AH
Am J Hematol; 2012 Feb; 87(2):226-8. PubMed ID: 22189940
[TBL] [Abstract][Full Text] [Related]
43. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
44. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
45. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.
Armeanu S; Krusch M; Baltz KM; Weiss TS; Smirnow I; Steinle A; Lauer UM; Bitzer M; Salih HR
Clin Cancer Res; 2008 Jun; 14(11):3520-8. PubMed ID: 18519785
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells.
Bugide S; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3509-E3518. PubMed ID: 29581297
[TBL] [Abstract][Full Text] [Related]
47. Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Tsunematsu H; Aono S; Shimizu S; Kodama T; Hikita H; Yamamoto M; Oze T; Aketa H; Hosui A; Miyagi T; Ishida H; Hiramatsu N; Kanto T; Hayashi N; Takehara T
Cancer Immunol Immunother; 2012 Sep; 61(9):1425-32. PubMed ID: 22302133
[TBL] [Abstract][Full Text] [Related]
48. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
49. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
50. Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model.
Lee DH; Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho E; Lee JH; Yu SJ; Kim YJ; Yoon JH
Cancer Biol Ther; 2017 Jan; 18(1):67-75. PubMed ID: 28055304
[TBL] [Abstract][Full Text] [Related]
51. IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction.
Easom NJW; Stegmann KA; Swadling L; Pallett LJ; Burton AR; Odera D; Schmidt N; Huang WC; Fusai G; Davidson B; Maini MK
Front Immunol; 2018; 9():1009. PubMed ID: 29867983
[TBL] [Abstract][Full Text] [Related]
52. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
[TBL] [Abstract][Full Text] [Related]
53. Sunitinib Induces NK-κB-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells.
Huang YX; Chen XT; Guo KY; Li YH; Wu BY; Song CY; He YJ
J Immunother; 2017 Jun; 40(5):164-174. PubMed ID: 28452850
[TBL] [Abstract][Full Text] [Related]
54. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A.
Busche A; Goldmann T; Naumann U; Steinle A; Brandau S
Hum Gene Ther; 2006 Feb; 17(2):135-46. PubMed ID: 16454647
[TBL] [Abstract][Full Text] [Related]
55. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
56. The miR-561-5p/CX
Chen EB; Zhou ZJ; Xiao K; Zhu GQ; Yang Y; Wang B; Zhou SL; Chen Q; Yin D; Wang Z; Shi YH; Gao DM; Chen J; Zhao Y; Wu WZ; Fan J; Zhou J; Dai Z
Theranostics; 2019; 9(16):4779-4794. PubMed ID: 31367257
[TBL] [Abstract][Full Text] [Related]
57. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
[TBL] [Abstract][Full Text] [Related]
58. Suppression of murine tumour growth through CD8
Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
[TBL] [Abstract][Full Text] [Related]
59. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.
Li Z; Gong H; Liu Q; Wu W; Cheng J; Mei Y; Chen Y; Zheng H; Yu X; Zhong S; Li Y
Immunology; 2020 Apr; 159(4):384-392. PubMed ID: 31849039
[TBL] [Abstract][Full Text] [Related]
60. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin.
Ma B; Wang Y; Zhou X; Huang P; Zhang R; Liu T; Cui C; Liu X; Wang Y
J Cancer Res Clin Oncol; 2015 Mar; 141(3):419-29. PubMed ID: 25240826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
